Key result
Metformin treatment significantly reduced serum visfatin and resistin levels in women with polycystic ovary syndrome, with no significant change in adiponectin levels.
Why the study?
Does metformin improve adipokine profiles (visfatin, adiponectin, resistin) in women with polycystic ovary syndrome?
Population
49 women, comprising 24 women with polycystic ovary syndrome and 25 healthy, age- and weight-matched…
Comparison
Metformin treatment vs Healthy controls and baseline values
Design
Cohort
Authors
Loading...
Metformin-associated reductions in visfatin and resistin in PCOS are hypothesis-generating; randomized trials needed before clinical adoption or cardiometabolic inferences.
Observational (n=49)
Does metformin improve adipokine profiles (visfatin, adiponectin, resistin) in women with polycystic ovary syndrome?
Metformin treatment reduces serum visfatin and resistin levels in women with PCOS, suggesting a potential mechanism for its insulin-sensitizing effects.
Tarkun et al. (2010) conducted an observational in Polycystic ovary syndrome (PCOS) (n=49). Metformin vs. Baseline (before treatment) and healthy controls was evaluated on Serum visfatin, adiponectin, and resistin levels. Metformin treatment significantly reduced serum visfatin and resistin levels in women with polycystic ovary syndrome, with no significant change in adiponectin levels.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: